LOVELAND, Colo., Nov. 1, 2017 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA - News; "Heska" or the "Company"),a provider of advanced veterinary diagnostic and specialty products, announced today an agreement to supply over 100 PetVetCare Centers ("PetVetCare") veterinary hospitals with in-house laboratory diagnostic equipment and supplies through 2024,
Under the agreement, Heska's in-house blood diagnostics analyzers will be placed into PetVetCare's general, specialty referral, and emergency hospitals throughout the United States. PetVetCare is one of the nation's top five veterinary healthcare providers and currently represents roughly 0.5% of full-service veterinary hospitals in the United States. As PetVetCare grows, new hospitals acquired and added will benefit from the Heska program. Included in the program are Heska's Element DC® Chemistry, Element HT5™ Hematology, Element POC™ Blood Gas & Electrolyte, and Element i™ Immunodiagnostics analyzers, along with October's newly released Element COAG™ analyzer, which performs coagulation, fibrinogen and blood typing tests. Upgrades to Heska solutions have begun in select PetVetCare hospitals and will be broadly released throughout 2018 as requested by each PetVetCare local leadership team.
Steve Eyl, Heska's Executive Vice President, commented, "After successfully completing a lengthy and thorough evaluation for accuracy and workflow, Heska is honored to have been selected as PetVetCare's long-term provider of mission critical blood diagnostics. This is a key account for Heska for Heska's new corporate and strategic accounts initiative and represents significant competitive market share shift to Heska. PetVetCare Centers is rapidly growing and is a respected leader in implementing technology and best practices into veterinary medicine. Their commitment to respecting each hospital, community, and pet family as unique and deserving of the highest levels of people, investment, and technology aligns perfectly with our Heska culture. We are thrilled to have been chosen from a highly competitive field by PetVetCare Centers and we look forward to growing with them for many years to come."
Heska Corporation (NASDAQ:HSKA - News) sells advanced veterinary diagnostic and specialty products. Heska's state-of-the-art offerings include blood testing instruments and supplies, digital imaging products, software and services, vaccines, local and cloud-based data services, allergy testing and immunotherapy, and single-use offerings such as in-clinic diagnostic tests and heartworm preventive products. The Company's core focus is on supporting veterinarians in the canine and feline healthcare space. For further information on Heska and its products, visit www.heska.com.
Contact Heska today at 800.464.3752 and visit www.heska.com for more information.
This announcement contains forward-looking statements regarding Heska's future financial and operating results. These statements are based on current expectations and are subject to a number of risks and uncertainties. Investors should note that there is an inherent risk in using past results, including trends, to predict future outcomes, including financial results and perceived customer behavior. Factors that could affect the business and financial results of Heska generally include, but are not limited to, the following: risks related to reliance on third parties to develop and manufacture products for Heska; risks related to the commercialization of new products; uncertainties related to attempts to expand into international markets, including, but not limited to, uncertainties related to timing, profitability and currency effects; uncertainties related to Heska's ability to measure and predict trends in the veterinary market; uncertainties related to Heska's ability to measure and predict the effectiveness of commercial relationships; uncertainties related to the future impact of recent business development activity; risks related to Heska's reliance on third-party suppliers, which is substantial; competition; and the risks set forth in Heska's filings and future filings with the Securities and Exchange Commission, including those set forth in Heska's Quarterly Report on Form 10-Q for the period ended June 30, 2017.
© 2017 Heska. All rights reserved. Element COAG is a registered trademark of Heska Corp. Specifications, prices, design, and availability subject to change without notice. Claims and offers subject to terms and conditions. Contact Heska for details.
View original content:http://www.prnewswire.com/news-releases/heska-announces-7-year-agreement-with-petvetcare-centers-300546798.html
SOURCE Heska Corporation
Subscribe to our Free Newsletters!
Encephalocele is a birth defect where a sac like protrusion of brain and covering membranes occurs ...
Bronchopulmonary dysplasia or chronic lung disease of infancy is seen in premature and low birth ...
Ear, nose and throat are important organs and disease in one area can affect the others. ENT ...View All